Jylamvo is an oral solution that contains 2 mg/ml of methotrexate. The product was granted a European Marketing Authorisation by the European Medicines Agency (EMA) on 29 March 2017.

Jylamvo is authorised for use in the following indications:

In rheumatological and dermatological diseases

Active rheumatoid arthritis in adult patients.

Polyarthritic forms of active, severe juvenile idiopathic arthritis (JIA) in adolescents and children aged 3 years and over when the response to non‑steroidal anti‑inflammatory drugs (NSAIDs) has been inadequate.

Severe, treatment‑refractory, disabling psoriasis which does not respond sufficiently to other forms of treatment such as phototherapy, psoralen and ultraviolet A radiation (PUVA) therapy and retinoids, and severe psoriatic arthritis in adult patients.

In oncology

Maintenance treatment of acute lymphoblastic leukaemia (ALL) in adults, adolescents and children aged 3 years and over